Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NGM Biopharmaceuticals

Explore full profile

A clinical-stage biopharmaceutical company which engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases

South San Francisco, United StatesFounded 2007Biotech & Life Sciences
Revenue $12M Latest reported FY
Total funding $100–500M Disclosed equity funding

About NGM Biopharmaceuticals

NGM Bio is a biopharmaceutical company dedicated to discovering and developing novel medicines aimed at transforming the lives of patients affected by serious diseases. The company employs a biology-centric drug discovery approach, integrating complex disease biology with protein engineering to generate proprietary insights. These insights are used to create promising product candidates that can quickly advance into proof-of-concept studies. NGM Bio's research and development engine is highly productive, with all therapeutic candidates in its pipeline originating from its in-house discovery efforts. The company serves patients with unmet medical needs and operates in the biopharmaceutical market. NGM Bio's business model focuses on leveraging its scientific expertise to develop and commercialize new therapies, thereby generating revenue through the successful advancement and eventual market introduction of its drug candidates. Currently, the company has four programs in active clinical development, supported by a strong financial position and a healthy cash runway. Keywords: biopharmaceutical, drug discovery, protein engineering, disease biology, patient needs, clinical development, research, development, medicines, therapeutic candidates.

Source: Dealroom company data

At a glance

Founded
2007
Headquarters
South San Francisco, United States
Listing
IPO 2019
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • The Column Group
  • Prospect Venture Partners
  • Rho Ventures
  • Rho Capital Partners

Series B and later3 investors entered at this stage

  • TopSpin Marketing Group, Inc.
  • Solon Mack Capital
  • Merck & Co.
Employees mapped 76 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 21 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
4K monthly visits
across markets
🇺🇸 United States77.5%
🇮🇳 India22.5%
Top 2 markets shown

Patents

Estimated portfolio value
$86M

41 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NGM Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NGM Biopharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.